DGKA (E2Z7V) Rabbit mAb #16775
- WB
- IP
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 80 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
Storage
Protocol
Specificity / Sensitivity
DGKA (E2Z7V) Rabbit mAb recognizes endogenous levels of total DGKA protein.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu734 of human DGKA protein.
Background
Diacylglycerol kinase alpha (DGKA) is a type 1 diacylglycerol kinase that competes with protein kinase C to convert messenger diacylglycerol (DAG) to phosphatidic acid (1). Upon activation of this intracellular lipid kinase, DGKA rapidly relocates from the cytosol to the plasma membrane where it is involved in multiple cellular processes, including regulating lipid and glucose metabolism levels, cell growth, and cell signaling (2,3). Expression of DGKA is high in T lymphocytes, and detectable in endothelial cells, epithelial cells, fibroblasts, and oligodendrocytes (4). DGKA negatively regulates T cell receptor-dependent responses through phosphorylation of phospholipase C-derived DAG (5-7). In contrast, DGKA-dependent phosphatidic acid generation by phosphorylation of a pre-existing DAG pool is necessary for IL-2-dependent T cell proliferation (8). DGKA is frequently overexpressed in cancer, promoting tumor cell survival, proliferation, invasion, and metastasis (9-12). Due to its role in immunity and cancer, targeting DGKA represents a unique opportunity for therapeutic intervention in cancer (13).
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.